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Perinatal human immunodeficiency virus type 1 (HIV-1) infections cause a broad spectrum of clinical
disease and are variable in both the age of the patient at onset of serious disease and the progression of the
clinical course. Heterozygotic perinatally infected twins with a marked difference in their clinical courses were
monitored during the first 2 years of life. Twin B, the second-born twin, developed AIDS by 6 months of age
and died at 22 months of age, while twin A remained minimally symptomatic through the first 2 years.
Sequential blood specimens were obtained from the twins in order to characterize the immunologic properties
of the children and the phenotypes and genotypes of the HIV-1 isolates at various times. Twin A developed
neutralizing antibodies and a high-level antibody-mediated cellular cytotoxicity (ADCC) response, while twin
B had no neutralizing antibody and a much lower ADCC response. The virus isolates obtained from the two
children at various time points proliferated equally well in peripheral blood mononuclear cells, were non-
syncytium inducing, and could not infect established T-cell lines. They differed in their ability to infect primary
macrophages. In parallel to the biological studies, the HIV-1 tat and part of the env gene sequences of the
longitudinal isolates at four time points were determined. Sequences of virus from both twins at different time
points were highly conserved; the viruses evolved at a similar rate until the last analyzed time point, at which
there was a dramatic increase in sequence diversity for the sicker child, especially in the tat gene. Our results
show that the viruses isolated at different times do not have significant changes in growth properties. The
absence or low levels of neutralizing antibodies may correlate with disease progression in the twins.
Perinatal human immunodeficiency virus type 1 (HIV-1)
infection presents a unique setting for investigating HIV-1
pathogenesis. The timing of infection can be defined within a
specific period, and events can be characterized sequentially.
The evolution of disease in perinatally infected children is
characterized by two different patterns (2, 20, 40). In the first,
infants develop severe disease, including AIDS, within the first
few months of life and their course progresses rapidly. This
pattern is usually associated with a concomitant steep decline
in CD4 cell numbers within the first 12 to 24 months of age.
The natural history of disease associated with the second pre-
sentation is more variable, but the course of disease is gener-
ally more indolent, with the onset of serious disease often
delayed for several years, and the CD4 cell numbers decline
more slowly. Some children in this group survive into early
adolescence.
It is not clear what factors are responsible for this difference
in the evolution of perinatally acquired HIV-1 infection. The
timing of perinatal infection, in utero or at delivery, as deter-
mined by the initial detection of virus at delivery or later, has
been proposed as a determinant of disease onset and progres-
sion (12). In a study from the Centers for Disease Control and
Prevention, infants with positive virus cultures or positive PCR
at delivery had a greater risk for early and severe disease than
infants in whom virus was not detected until after the first week
of age (34). The severity of the maternal disease stage during
pregnancy has also been directly associated with risk of early
disease in infants (3, 40). In a study by investigators in France,
infants born to mothers with AIDS had a substantially greater
risk of having AIDS by 1 year of age than infants born to
asymptomatic mothers (2). Whether this risk is related to virus
burden, virus phenotype, or other factors has not been deter-
mined.
In adults, the appearance of virus with the ability to form
syncytia or replicate to high titers has been associated with
disease progression (9, 39). The role of viral phenotype in the
evolution of disease in children has not been described. Other
viral factors, such as genetic variation, could also be important
in disease progression (25). Studies evaluating the genetic di-
versity of virus in perinatally infected infants have found a
homogeneous sequence population in infants at birth (30, 42);
others have suggested that multiple maternal genotypes are
present in infected children (26). Very little, however, is known
about the correlation between genetic variability and disease
progression over time in adults or children.
Multiple factors are likely to alter the course of disease in
children. The occurrence of divergent courses of disease in
perinatally infected children provides the opportunity for iden-
tifying viral or immunologic factors that influence the natural
history of perinatally acquired HIV-1 infection and disease.
Perinatally infected heterozygotic twins with divergent clinical
courses were monitored until almost 24 months of age. Se-
quential specimens from the twins were studied retrospectively
to characterize the immune response and viral phenotype and
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genotype for each twin over time. Our results suggest that the
absence of neutralizing antibodies can distinguish infants with
differing disease courses.
MATERIALS AND METHODS
Cell cultures. Healthy-donor peripheral blood mononuclear cells (PBMC)
were obtained from leukopacs (American Red Cross). The cells were purified on
Lymphocyte Separation Medium (Organon Teknika, Durham, N.C.) and prop-
agated in RPMI 1640 medium containing 10% heat-inactivated fetal bovine
serum (FBS) and 5 mg of phytohemagglutinin (Difco) per ml for 24 h before
coculture with patient PBMC or infection with culture supernatant containing
HIV-1. Primary monocytes were obtained from gradient-purified PBMC by the
plastic adherent technique (7). Adherent cells were cultured for 7 to 10 days in
RPMI 1640 medium containing 10% FBS and 10 ng of granulocyte-macrophage
colony-stimulating factor (GIBCO) per ml to allow differentiation into macro-
phages.
Virus culture and phenotype and tropism determination. HIV-1 was isolated
by standard coculture procedures (18). In brief, patient PBMC were cocultivated
with an equal number of phytohemagglutinin-stimulated PBMC from an HIV-
1-seronegative donor (final concentration, 2 3 106 PBMC per ml). Half of the
culture medium was replaced with fresh medium twice a week, and equal num-
bers of fresh uninfected phytohemagglutinin-stimulated PBMC were added to
the culture once a week. Virus production was monitored by measuring HIV-1
p24 antigen levels with a commercial enzyme-linked immunoassay kit (Coulter
Corporation, Hialeah, Fla.). Virus stocks were prepared when p24 antigen ex-
ceeded 10 ng/ml, and titers were determined by limiting dilution to obtain the
50% tissue culture infectious dose (TCID50) (see below).
Syncytium-inducing (SI) or non-syncytium-inducing (NSI) phenotype was de-
termined by infecting MT2 cells in duplicate microtiter wells in a 96-well flat-
bottomed plastic tissue culture plate with 50 ml of fresh virus stock (21). Virus
was scored as SI if three to five syncytia were observed per well within a 14-day
period and as NSI if syncytia failed to form in that time.
To determine viral tropism for various host cell types, human PBMC, primary
macrophages, and T-cell lines CEM and H9 were infected with the virus stock by
a standard method (27). Briefly, cells were treated with 2 mg of Polybrene per ml
(1 h at 378C) and then incubated with virus stock (10 to 15 ng of HIV-1 p24
antigen per 5 3 105 host cells; incubation for 2 h at 378C), washed, and sus-
pended in fresh culture medium. Supernatants were removed at various times
postinfection and assayed for HIV-1 p24 antigen.
Virus titration and TCID50 calculation. Stocks of virus obtained from the
children at the different time points were thawed and serially diluted fivefold,
starting with a dilution of 1:5. Two hundred microliters of each virus dilution was
incubated in duplicate with 0.3 ml of pooled PBMC containing 106 cells in
eight-strip cluster tubes (Costar, Cambridge, Mass.) for 1 h at 378C in a 5% CO2
incubator. The cells were washed twice, resuspended to 0.2 ml with complete
medium, and transferred to 48-well plates containing 0.8 ml of medium per well.
Four days after infection, 0.5 ml of culture supernatants from each well was
replaced with 0.5 ml of supernatant fresh medium. At days 7 and 10 postinfec-
tion, 0.5 ml of supernatant in each well was replaced with 0.5 ml of PBMC
suspension containing 106 cells. Virus production was estimated at day 14 postin-
fection by measuring the HIV-1 p24 antigen level. One TCID50 unit was defined
as the virus dilution required to infect half of the replicate cultures.
Neutralization of autologous virus. Plasma specimens were heat inactivated at
568C for 30 min and serially diluted fourfold in complete medium, starting with
a 1:5 dilution. Fifty microliters of each plasma dilution was incubated in duplicate
with 0.2 ml of 100, 50, 25, or 12.5 TCID50 units of autologous virus cultured from
the same time point, at 378C for 1 h in 5% CO2. Two hundred fifty microliters of
pooled PBMC containing 106 cells was added, and the mixture was incubated
overnight. The cells were then washed twice, resuspended in 0.2 ml of complete
medium, and transferred to a 48-well tissue culture plate containing 0.8 ml of
medium per well. Four and seven days later, 0.5 ml of culture supernatants was
removed for p24 antigen determination. Medium was replaced on day 4, and on
day 7 the culture was terminated. Samples with p24 levels above the range of the
assay were diluted and reassayed. For each virus input and plasma dilution, the
percent inhibition was calculated as follows: 100 2 (p24 antigen production in
tubes containing serum/p24 antigen production in tubes with no serum) 3 100.
HIV-1 ADCC assay. Antibody-dependent cellular cytotoxicity (ADCC) anti-
bodies specific for HIV-1 Env protein were measured by a standard chromium
release assay. D-2 cells, chemically transformed mouse fibroblasts (a gift from
Thomas Leist, Cornell Medical Center), infected with a vaccinia virus recombi-
nant, vPE8 (AIDS Reference Reagent Repository), were used as target cells. D-2
cells infected with vaccinia virus and uninfected D-2 cells were also used in each
assay as controls. To prepare the target cells, D-2 cells were grown to semicon-
fluency in RPMI 1640 medium with glutamine, 10% FBS, and 0.1% gentamicin
for 24 h. The cells were trypsinized and washed, and 2 3 106 cells were labelled
with 200 mCi of 51Cr for 1 h at 378C. After being labelled, the cells were infected
with the recombinant virus or control vaccinia virus at a multiplicity of infection
of 10 PFU per cell in a volume of 1.0 ml of medium. A third population of
uninfected control cells was adjusted to a total volume of 1.0 ml and thereafter
treated similarly to the infected cells. After incubation at 378C (5% CO2) for 2.5
h, the cells were washed three times in RPMI 1640 medium with 10% FBS and
resuspended to a final concentration of 104 cells per 50 ml. For the assay, 104 cells
were added per well. PBMC from a healthy uninfected donor previously deter-
mined to have a high level of ADCC activity were separated with Lymphocyte
Separation Medium and washed three times, and the cell concentration was
adjusted to provide effector-to-target cell ratios as indicated below (see Fig. 1).
Three different effector-to-target cell ratios were used in each assay to verify the
specificity of the lytic activity observed.
Sera were heat inactivated, and 50 ml of serum was added to each well. Target
cells were incubated with sera at 48C for 45 min. A single concentration of serum
(1:200, final dilution) was tested in each assay. In addition to the test sera, each
assay also included vaccinia virus-positive sera and vaccinia virus-negative and
HIV-1-negative sera as controls. For the assay, control and test samples were
tested in duplicate in 96-well U-bottom microtiter plates. Spontaneous release
and maximum release were each tested in six wells, and a mean value was
calculated for each. Serum was first added to the wells, and then 50 ml of target
cells and 100 ml containing the effector cells were added. The plates were
incubated for 6 h at 378C in 5% CO2 and centrifuged at 400 3 g for 10 min. Fifty
microliters of supernatant from each well was transferred to a counting tube for
measurement of 51Cr release. For each serum sample tested, lysis was calculated
as follows: [(average cpm of sample 2 average cpm of spontaneous release)/
(average cpm of maximum release 2 average cpm of spontaneous release)] 3
100.
To determine HIV-1-specific cytotoxicity, percent lysis of the vaccinia virus-
seropositive or vaccinia virus- and HIV-1-seronegative sera (whichever was
greater) was subtracted from percent lysis of the test sera.
DNA preparation, PCR analyses, and cloning. High-molecular-weight DNA
was obtained from infected cells by a standard proteinase K digestion method
(1). Briefly, 1 3 107 to 3 3 107 infected cells were resuspended in 0.3 ml of
digestion buffer (100 mM NaCl, 10 mM Tris-HCl [pH 8.0], 25 mM EDTA [pH
8.0], 0.5% sodium dodecyl sulfate, and 100 mg of proteinase K per ml) and
incubated at 508C overnight. The digested samples were then extracted with
phenol-chloroform-isoamyl alcohol (25:24:1) and dialyzed against TE buffer (10
mM Tris-HCl, 1 mM EDTA; pH 8.0) overnight, and the DNA concentration was
quantified by UV absorbance. The HIV copy number of each DNA preparation
from different time points was determined by semiquantitative PCR by methods
described previously (43). DNA samples containing about 500 HIV-1 target
molecules per sample were used for PCR.
All the primers for PCR were designed by using the HIV-1 conserved se-
quences published in the Human Retrovirus and AIDS Sequence Data Base
(31). The positions of each primer correspond to the positions of HIV-1 HXB2
viral sequence. Primers for amplification and cloning of the viral envelope V3
loop and CD4 binding region are as follows: HENV-1, 59-GTATGAATTCAA
CTGCTGTTAAATGGCAGT-39 (positions 6986 to 7015; an EcoRI site is
shown underlined); and HENV-2, 59-TATAGAATTCACTTCTCCAATTGTC
CCTCAT-39 (positions 7676 to 7646; an EcoRI site is underlined). HENV-1,
HENV-2, and HENV-5 (59-GTTTTATTCTGCATGGGAGTGTGAT-39; posi-
tions 7487 to 7463) were used as primers for performing DNA sequence analyses.
TAT-F (59-TTTCAGAATTGGATGCCGACATA-39; positions 5771 to 5793)
and TAT-R (59-GGACCACACAACTATTGCTATTATT-39; positions 6132 to
6108) were used to amplify and clone the viral tat gene exon 1.
PCR mixtures consisted of 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1%
Triton X-100, 1.5 mM MgCl2, 20 pmol of each primer, 1 mg of high-molecular-
weight DNA, 0.25 mM (each) deoxynucleoside triphosphates, and 2.5 U of Taq
polymerase. The reaction was carried out in a total volume of 100 ml. The first
cycle was 948C for 3 min, 728C for 2 min, and 508C for 1 min 30 s and was
followed by 35 cycles of 948C for 45 s, 728C for 2 min, and 558C for 1 min. The
last cycle was 948C for 45 s and 728C for 10 min. The PCR products were
separated on a 1% agarose gel and purified by electroelution. The purified DNA
fragments were ligated to the pGEM T-vector according to the procedures
recommended by the manufacturer (Promega, Madison, Wis.).
DNA sequencing and analysis. Sequence data were obtained by using a com-
mercial sequencing kit (U.S. Biochemicals, Columbus, Ohio) based on the
dideoxynucleotide termination method (35). Sequence analyses were carried out
with the Genetics Computer Group, Inc. (Madison, Wis.), sequence analysis
package. DNA sequences were also aligned manually. Nucleotide gaps were
assigned after amino acid conversion to maintain translation integrity. Nucleo-
tide gaps and insertions were commonly found in the V4 region even in different
sequences from the same individual. Nucleotide distances were determined by
using the DNASTAR program (DNASTAR, Madison, Wis.). Alignment gaps
were not counted as differences.
Phylogenetic analyses were performed by using the program PHYLIP, version
3.5c (13). Five hundred bootstrap sequence sets were generated, parsimony
analyses were performed with universal branch swapping, and a consensus tree
was constructed. A time scale was added to the trees by using the dates of sample
collection (19).
Nucleotide sequence accession numbers. The GenBank accession numbers for
the env sequences are U47562 to U47588, and the numbers for the tat sequences
are U47589 to U47613.
3590 HUTTO ET AL. J. VIROL.
 by on February 7, 2009 
jvi.asm.org
D
ow
nloaded from
 
  
RESULTS
Clinical disease course. Twins A and B were born to a
29-year-old multigravida mother who received no prenatal care
and whose own infection was not diagnosed until after the
birth of the twins. The mother had no history of drug use or
previous blood transfusions. The twins have several siblings,
but none were HIV seropositive. The infants were delivered by
cesarean section because of failure of labor to progress. Twin
A, the healthier twin, was born first, weighing 3.41 kg, and twin
B weighed 3.0 kg. Because of maternal endometritis and a
positive urine antigen test for group B streptococcus in both
infants, both received antibiotics for 10 days. Their nursery
course was not remarkable otherwise.
The infants were first tested for HIV-1 at 6 weeks of age.
Virus cultures from both infants were positive. The infants,
however, were asymptomatic at this time, with normal physical
examinations (Table 1). At 6 weeks (1.5 months), the CD4
count was already significantly lower for twin B (699/mm3)
than for twin A (1,882/mm3). Twin B subsequently developed
failure to thrive, esophagitis at 6 months of age, and enceph-
alopathy. She had numerous infections and was hospitalized six
times before her death at 22 months of age. In contrast, twin A
had minimal clinical symptoms (lymphadenopathy, hepato-
megaly, and chronic otitis media and radiographic evidence of
lymphoid interstitial pneumonitis) during the first 24 months of
life, and her CD4 counts remained .1,500/mm3.
ADCC. Lysis of cells expressing HIV-1 gp120 by ADCC was
measured for both twins, with serum samples obtained at 1.5,
10, 13.5, and 20 months of age (Fig. 1). At 1.5 months, the
degree of lysis was very low for both infants (10% or less). At
10 months, the level of lysis was distinctly different between the
twins and remained different in all sequential serum specimens
tested. Sera from twin A, the healthier twin, had .40% lysis at
10 months, but lysis in twin B was still only about 10%. At 13.5
and 20 months, lysis of cells by serum from twin B was almost
20%, but this level was at least one-third less than that mea-
sured for twin A.
Neutralizing antibodies. Autologous neutralizing-antibody
reactivity in the plasma of the twins was tested. For twin A,
plasma samples were available at ages 1.5, 3, and 25 months.
For twin B, autologous neutralization was tested for virus-
plasma pairs at 1.5, 3, 10, and 13.5 months of age. As shown in
Fig. 2, twin A had no neutralizing antibodies at 1.5 months, but
by 3 months of age neutralization of the autologous isolate was
already evident. The levels of neutralizing-antibody reactivity
increased with time, and at 25 months of age, the level of
neutralizing-antibody reactivity was higher than in the previous
plasma samples. Twin B did not develop any measurable neu-
tralizing antibodies in any of the sequential plasma samples
tested, suggesting that the absence of neutralizing antibodies
may correlate with disease progression.
Viral growth properties and host cell tropism. Studies were
carried out to examine the growth properties of the different
viral isolates from the twins at various times. Five isolates from
each child were studied. For twin A, isolates taken at 1.5, 3, 10,
13.5, and 25 months were studied. For the sicker twin (B),
isolates taken at 1.5, 3, 10, 13.5, and 16 months were studied.
The viruses, isolated from minimally cultured PBMC, were
further characterized for their growth characteristics. The vi-
ruses isolated from the two children at various times grew
equally well in PBMC (Table 2). They were all NSI, and none
of the isolates grew in CEM or H9 T-cell lines. Even the last
available isolate obtained from twin B, at 16 months, prior to
death, displayed no SI phenotype and could not grow in H9
cells. All the isolates from the five time points from the health-
ier twin A grew in macrophages but less well than positive-
control macrophage-tropic HIV-1 isolate 128A. In contrast, for
the sicker twin (B), viruses from the earlier time points grew
very well in macrophages, similar to the positive control. How-
ever, their ability to grow in macrophages decreased with time,
and by 16 months, the virus displayed only minimal macro-
phage tropism. These differences in tropism are unlikely to be
due to differences in input virus titer, because the p24 titers
and TCID50 of the viruses were equalized before infection. In
addition, subsequent passages of virus from each time point for
both children were tested, and their macrophage tropism was
confirmed (data not shown).
Molecular cloning and sequence analyses. In parallel with
our studies of the biological properties of the HIV-1 isolates,
the genetic sequences of the longitudinal viral isolates were
also determined. The env gene from each isolate at four time
points for each twin was cloned and sequenced; the region
analyzed included the V3, V4, and CD4 binding domains (Fig.
3). In addition, the tat gene sequences of the longitudinal
isolates were also determined in order to obtain an estimate of
the rate of evolution of the virus in the absence of the strong
TABLE 1. Clinical histories of the twinsa
Date
(mo/yr)
Age
(mo)
Finding(s) for twinb: Absolute CD4 T-cellno./mm3
A B Twin A Twin B
04/92c,d 1.5 Normal exam Normal exam 1,882 699
06/92c,d 3 LAD Hepatomegaly, LAD NDe ND
10/92 6 HSM Hepatomegaly, LAD, esophagitis, AIDS 1,774 94
01/93c,d 10 LAD, HSM LAD, hepatomegaly, developmental delay ND ND
04/93c,d 13.5
08/93d 16 Recurrent otitis media, LAD, HSM Pneumonia and sepsis, hepatomegaly,
developmental delay
1,347 64
12/93 20 Not seen Pneumonia and sepsis, esophagitis, herpes
simplex stomatitis, developmental delay
ND ND
02/94 22 Chronic otitis media, LIP, LAD, HSM Acute respiratory failure, death ND ND
05/94d 25 Chronic otitis media, LAD, HSM, LIP 1,556
a Both twins are female.
b LAD, lymphoadenopathy; HSM, hepatosplenomegaly; LIP, lymphoid interstitial pneumonitis.
c HIV-1 genetic analyses were performed.
d HIV-1 cell tropism analyses were performed.
e ND, not determined.
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selection pressure reflected by changes in the env gene (Fig. 4).
Five env clones and at least five tat clones from each isolate at
each time point (a total of 40 env clones and 42 tat clones) were
sequenced and aligned. Because of gaps and insertions, the
nucleotide lengths of the env sequences varied from 526 to 570
bases. There were 27 different env forms among the 40 clones.
One env sequence had a mutation which resulted in a frame-
shift. The tat sequences were uniform in length (219 bases).
There were 21 different tat forms among 42 clones sequenced.
The nucleotide sequences from different time points and from
different twins were highly conserved. Phylogenetic analysis
comparing the env V3, V4, and CD4 nucleotide sequences
shows that even though the sequences from the twins are
highly conserved, sequences from each twin seem to cluster
more closely to each other and are distinct from the clade B
consensus sequence (data not shown). The most diverse se-
quences of the different env genes from the twins still had
about 97% identity. The intraindividual differences in nucleo-
tide sequence between isolates from different time points are
shown in Table 3. The env gene from each of the twins had
approximately the same rate of diversification from the first to
the last time points (1.9 3 1022 nonsilent changes per nucle-
otide per year for twin B and 1.73 1022 for twin A). The silent
mutations from the first to last time points are 7 3 1023
changes per nucleotide per year for twin B and 4 3 1023 for
twin A. In contrast, the tat gene for the sicker twin B had 6
times more nonsilent changes than twin A (1.93 1022 changes
per nucleotide per year versus 3.2 3 1023) and 4.5 times more
silent changes than twin A (7.3 3 1023 changes per nucleotide
per year versus 1.6 3 1023), with most of the differences
occurring at the last time point.
When the V3 sequences were aligned, all the isolates dis-
played sequences that were found in typical macrophage-tropic
HIV-1 isolates. There are four different forms of V3 sequences
among the sequenced clones. They are represented by clones
A1-E1, A3-E1, A10-E1, and B13-E5 (Fig. 3 and 5). No signif-
icant differences in the V3 region were observed between iso-
lates that displayed macrophage tropisms (twin B) and those
that did not (twin A) (Fig. 3). Our sequences nevertheless are
more similar to those of cloned HIV-1 strains that display
macrophage tropism (SF128A, JRFL, BAL1, and SF162) than
to those of strains that display T-cell tropism (SF2, IIIB, and
NL43). Several amino acids (positions 13, 23, and 27) that were
found to be conserved in many different macrophage-tropic
strains were also found in our clones (Fig. 5) (8). It has been
suggested that the overall charge of the V3 loop at pH 7
correlates with the ability of HIV-1 to induce syncytia (14).
Strains with higher charges can induce syncytia, and those with
lower charges cannot. Interestingly, the overall charge of the
V3 loop of our clones from both twins is found to be around 3.
These low net charges correlate well with the NSI phenotype of
the isolates (Fig. 5).
To further determine the relationship between the HIV-1
clones from different time points, the sequences were also
analyzed by neighbor-joining and parsimony analyses. An evo-
lutionary tree was created from the parsimony analysis of these
sequences (Fig. 6). This tree shows the heritage of progeny
virus forms derived from earlier forms and the discontinuance
FIG. 1. Comparison of ADCC activities of the twins’ serum samples obtained at various time points. Percent ADCC was calculated from the amount of chromium
released after addition of the sera as described in the text. Different effector-to-target cell ratios were used in two separate assays to confirm the specificity of lysis. mo.,
months.
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of other branches. The divergence among viral forms in the
tree branches is represented by their vertical spread. For the
env gene sequences for twin A, the first time point began with
two distinct viral forms. However, only one viral form was
carried through to the last analyzed time point. Interestingly,
for twin B, the sicker child, greater diversity of the viruses was
observed at the fourth time point. Especially for the tat gene,
there was a dramatic change between time points 3 and 4, and
the viruses diversified and formed a distinct group. Separate
phylogenetic analyses using the neighbor-joining method of
linking maximum-likelihood distances confirmed these find-
ings for the env and tat genes (data not shown).
DISCUSSION
In these perinatally infected twins, clinical courses that were
distinctly different were noted within a few months after birth.
The different patterns of disease that occurred in these infants
were characteristic of the bimodal patterns of clinical disease
that have been described previously for children with perinatal
HIV-1 infection (2). One of the children, who developed an
AIDS-defining disease by 6 months of age that was associated
with a rapid decline in CD4 cell number, had a pattern of
early-onset disease with rapid progression. In comparison, her
twin was relatively healthy during the first 24 months of life,
with CD4 cell counts that were normal for her age. Her course
was typical of children having the second pattern of disease,
which is characterized by a more indolent disease process and
a comparatively longer survival.
Various factors have been proposed to explain differences in
the rate of disease progression between perinatally infected
children, including the rate of disease progression in the
mother at the time of infection (2, 40), the ability of the infant
to mount an immune response following infection (5), and
biological properties of the infecting virus (11, 39). In addition,
it has been shown that the timing of HIV-1 transmission from
mother to infant (in utero, at birth, or postpartum) correlates
with the rate of disease progression (12). Whatever the under-
lying cause of the difference, the twins in this study provided
the opportunity to compare specific virologic and immunologic
factors that may play a role in the differing patterns of disease
that occur in children. Our longitudinal and parallel charac-
terizations of humoral immunity and viral diversity and bio-
logic properties suggest that both immunologic and viral fac-
tors may distinguish the two disease courses.
Since this was a retrospective study, not all relevant speci-
mens were available. Specimens from the mother and infants
at birth and from the twin with early disease just prior to death
would have provided more-detailed information about the role
of virus phenotypes and genetic diversity in evolution of the
disease. In addition, the timing of perinatal transmission and
the role of viral burden in the two infants at birth could not be
examined, because birth specimens were not available. For
most time points studied, only viral isolates from cells that had
undergone minimal time in culture were available for study.
Our studies that compared the development of autologous
neutralizing antibodies and ADCC found clear differences be-
tween the two infants. Using contemporaneous virus isolates
and plasma specimens, we showed that neither infant had
antibodies capable of neutralizing autologous virus at 6 weeks
of age. By 3 months, however, the healthy twin had developed
neutralizing antibodies, while these antibodies were not
present in serum from the twin with early onset of disease at 3
months of age or in any subsequent sample studied. The lack
of neutralizing antibodies at 6 weeks of age in both twins
suggests that maternal neutralizing antibodies to the transmit-
ted virus were absent at birth and therefore were absent in the
FIG. 2. Neutralization of the twins’ viral isolates by their autologous sera
(1/20 dilution) at various times. Percent inhibition of p24 antigen production is
shown for different amounts of input virus as measured on day 7 after infection.
(A) Twin A; (B) twin B.
TABLE 2. Host cell tropism of various viral isolates from the twins
Isolate
P24 antigen production in the indicated host cellsa
PBMC Macrophages CEM H9
128A 740,000 1,582 —b —
SF2 32,550 19 — 48,570
A1c 726,400 149 11 1
A3 817,500 160 21 0
A10 375,300 319 5 2
A13 489,500 278 2 0
A25 — 154 — 2
B1 731,500 1,764 4 0
B3 781,600 2,022 3 0
B10 528,700 3,521 9 0
B13 362,700 839 4 2
B16 — 142 — 0
a Given in picograms of p24 antigen per ml measured after 14 days in culture.
b—, not tested.
c A1, viral isolate from twin A at 1 month of age; other isolates are designated
similarly.
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mother. This is in agreement with recently published studies
correlating the absence of maternal neutralizing antibodies
and a higher risk of infection of the infant (23, 36). De novo
production of antibodies by 3 months of age in the healthier
twin is consistent with reports indicating that new antibodies to
HIV-1 are detectable in some children between 3 and 6 months
of age (17, 33). The presence of an autologous neutralizing
antibody in infant specimens collected between 0 and 3 months
has been investigated previously (23). In that study, no neu-
tralizing antibodies were found in any of four children tested.
FIG. 3. Alignment of the envelope gene amino acid sequences from the V3 to CD4 binding domains of the various HIV-1 isolates from the twins. Five clones from
each twin at each time point were sequenced. A1-E1, envelope clone 1 from twin A isolate at 1 month of age; A3-E1, envelope clone 1 from twin A isolate at 3 months
of age; other clones are designated similarly. The consensus sequence (Consen.) of the V3 to CD4 binding domain region is listed at the top. Amino acids identical
to the consensus sequences (2), those that are different (lowercase), and gaps (dots) are indicated.
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Thus, this is the first report documenting the development over
time of an autologous neutralizing-antibody response in chil-
dren in correlation with disease progression. Even though no
autologous neutralizing-antibody response was found in the
sicker twin as determined by using contemporaneous plasma
specimens, it is possible that a delayed response to the virus
isolates occurred later. Because only a limited amount of
plasma from either twin was available, this question could not
be further explored. In addition, the lack of development of
autologous neutralizing antibodies in the sicker twin is not a
reflection of an absolute lack of de novo synthesis of antibod-
ies, as indicated by the detection of ADCC in this twin by 10
months of age.
The ability to form syncytia has been shown to correlate with
disease progression in adults (9, 39). Very little information is
known about this factor in children. Recent studies have sug-
gested that infants with viral isolates classified as rapid or
high-level virus producers and having the SI phenotype are
more likely to have rapid disease progression, while children
with slow or low-level virus production and NSI viral isolates
are likely to have a more indolent disease course (11, 38). With
our progressor twin B, even at the last time point character-
ized, the virus was NSI, displayed a low level of cytopathology,
and was unable to grow in T-cell lines; however, the last viral
isolate from twin B (fifth time point) seemed to be losing its
macrophage tropism. It cannot be ruled out that, prior to the
death of twin B, her virus may have acquired T-cell tropism, SI,
and a rapid- or high-level-producer phenotype.
Evolution of viral phenotypic properties can be attributed to
changes in HIV-1 sequence (31). The variable domains of the
gp120 env gene contain important determinants for viral host
cell tropism, for cytopathology in culture, and for host immune
FIG. 4. Alignment of the tat gene product amino acid sequences from the various HIV-1 isolates from the twins. Five clones from each twin at each time point were
sequenced. A1-T1, tat clone 1 from twin A isolate at 1 month; other clones are designated similarly. See the legend to Fig. 3 for details. Consen., consensus sequence;
*, stop codon.
TABLE 3. Nucleotide distances of twin A and B HIV-1 isolates at
different times
Gene segment
and isolatea
Internal variation
(%)b % Changes
c
V3-V4
A1 0.64
A3 0.53 2.13
A10 0.4 1.96
A13 0 2.09
B1 1.34
B3 0.5 2.51
B10 1.51 2.22
B13 1.21 2.69
Tat
A1 0.55
A3 1.19 1.10
A10 0.55 0.55
A13 0.50 0.46
B1 0
B3 0.18 0.09
B10 0.96 0.55
B13 1.74 2.65
a A1, viral isolate from twin A at 1 month of age; other isolates are designated
similarly.
b Average percent nucleotide distance between clones from the same isolate at
each time point.
c Percent nucleotide distance from sequence obtained at the first time point
for the same twin.
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responses to HIV-1 infection (6, 16). In particular, the well-
characterized V3 region of env has been found to determine
macrophage tropism (8, 16, 27, 32, 37). All of the V3 sequences
obtained from the twins have extensive identity with sequences
of macrophage-tropic HIV-1 isolates from adults. However,
the sequences of some isolates from twins A and B, which
display differences in macrophage tropism, have identical V3
sequences (for example, A10 and B1 [Fig. 3]), suggesting that
other viral sequences besides V3 may contribute to macro-
phage tropism (4, 15, 41). The net charge of the V3 region has
also been correlated with the SI or NSI phenotype (14). Based
on the overall charge of the V3 loop sequence, all our se-
quenced isolates display a relatively low overall charge, which
corresponded well with the observations that a low overall
charge in the V3 loop correlates with the NSI phenotype (14).
However, it is also possible that only a few SI virus particles
may exist at the different time points, insufficient to produce an
SI phenotype in our assay, and the cloning of viral sequences
may have missed these minor populations so that their se-
quences are not reflected in our analyses.
Studies of natural HIV-1 transmission have shown that the
recipients initially have a relatively homogeneous HIV-1 pop-
ulation, while the transmitters have a mixture of different vi-
ruses with a spectrum of genotypes and phenotypes (29). At
later times after infection, severalfold-greater diversity was
noted than at earlier stages of infection (28), suggesting that
FIG. 5. Alignment of the V3 sequences of the HIV-1 isolates from the twins. Amino acids identical to the consensus sequence (dashes), those that are different
(lowercase), and gaps (points) are indicated. Amino acids that were suggested to play important roles in determining HIV-1 macrophage tropism (8) are shaded. HIV-1
strains SF2, HTLV-IIIB, and NL43 are T-cell tropic (T). HIV-1 strains SF128A, BAL1, JRFL, and SF162 are macrophage tropic (M). The overall charge of each V3
domain was calculated at pH 7 by using the ISOELECTRIC program in the Genetics Computer Group sequence analysis package.
FIG. 6. Evolution over time of the viral env and tat gene sequences among the sequential isolates from the twins. Viral forms are designated by sequence number
(Fig. 3). Evolutionary heritage (solid lines), with number of nucleotide changes from the earlier form noted above the terminus, evolutionary heritage with no nucleotide
changes (dotted lines), and additional viral forms identical to the one designated (numbers in parentheses) are shown. The vertical spread of forms at a given time point
represents the internal diversity among forms according to the scale of nucleotide differences provided at the extreme right. Time points correspond to successive
sampling times for genetic analysis, with time 0 being a hypothetical time before which no sequence divergence had occurred.
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sequence diversity may correlate with disease progression (22).
Our results showed that diversity among viral forms increased
to a greater extent at the final time point for the twin who
progressed to AIDS than in the twin who did not. However, the
degree of divergence as represented by nucleotide distances in
our study should be met with some skepticism: it is based on a
small sample size of cloned viral isolates which may not rep-
resent what may be significant to pathogenesis in vivo. Since
the initial viral load cannot be determined, it will be impossible
to distinguish whether the greater viral sequence diversity oc-
curred in the sicker child because immune suppression allowed
the emergence of genetic variants or whether the increased
heterogeneity is generated by a high initial viral load in the
sicker child’s PBMC, leading to detection of additional minor
viral populations. In contrast, a study by Delwart et al. (10)
found a high degree of quasispecies complexity in the env gene
of virus from asymptomatic adults with a strong immune re-
sponse. These differences could be due to the above-men-
tioned limitations of sampling or could be the results of dis-
similar patient populations. Their study contrasted fast disease
progressors with slower progressors.
The possibility of PCR contamination in our sequence anal-
yses cannot be eliminated, especially in a situation in which the
patients have a shared epidemiology. PCR contamination
among samples has indeed been of major concern recently
(24). From our phylogenetic analysis, identical viral forms were
not found in the two children but were commonly found within
one twin. Viral forms obtained from the first time point for
twins A and B differed from each other by an average of 2.7%
(range, 2.2 to 3.7%) for the V3-V4 region and by 0.7% (range,
0.5 to 1.4%) for the tat region. These differences increased at
later time points. The clustering of sequences from twins A and
B within each twin suggests that there was no cross contami-
nation, at least not between the twins. The phylogenetic anal-
ysis including V3-V4 sequences from both patients along with
the consensus form of HIV-1 clade B also showed no signifi-
cant clustering between the twins’ sequences and clade B con-
sensus sequences.
Despite the drawbacks due to sample availability and the
limited number of viral isolates analyzed, our study with these
heterozygotic twins represents a nearly ideal opportunity to
monitor parallel viral phenotypic and genotypic changes and
their relationships to change in the immune response and
disease progression. It will still be important to examine the
immune response as well as the viral tat and env gene se-
quences of twin A further to determine if sequence homoge-
neity is maintained as long as the child is healthy. Further
studies using larger panels of longitudinal pediatric samples
are also necessary in order to confirm our initial findings.
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